What is the standard dosing protocol for Kisspeptin?

Conventional Kisspeptin dosing is 100-200 mcg 1-2x weekly subq via subq/iv (research). For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the evidence base for Kisspeptin?

Kisspeptin's evidence base sits at phase ii in hsdd, fertility. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The female physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What does Kisspeptin stack well with?

For female physiology protocols, Kisspeptin pairs with compounds on complementary pathways: Oxytocin, GHK-Cu, Epithalon. These pairings are selected because they engage independent receptor systems from Kisspeptin's primary mechanism (Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release), producing additive or synergistic effects rather than receptor competition.

How does Kisspeptin's half-life affect dosing?

Kisspeptin has a plasma half-life of ~28 min IV, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1-2x weekly subq dosing at 100-200 mcg per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

What should I look for in Kisspeptin sourcing and quality?

Acceptable Kisspeptin certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 1302 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Home/ Compounds/ Kisspeptin

Kisspeptin

Women's Health

Women's-health applications of Kisspeptin require explicit attention to cyclical hormonal context, contraceptive and pregnancy considerations, and — for users in perimenopause or postmenopause — integration with HRT. Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release This positions kisspeptin one step upstream of the entire reproductive endocrine axis. Effects on LH/FSH are tightly regulated and physiological — unlike exogenous HCG it does not bypass HPG feedback.. Dosing at 100-200 mcg 1-2x weekly subq via subq/iv (research) with cycle-phase-aware tracking is the standard protocol for premenopausal users.

Female Physiology Applications

Cycle SupportEndometriosis SupportAutoimmune SupportFertilitySkin Health

Key Takeaways

Female-physiology lens: Kisspeptin response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 100-200 mcg 1-2x weekly subq via subq/iv (research); cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, GHK-Cu, Epithalon.

Female Physiology Mechanism

Cyclical hormone background shapes how women experience Kisspeptin. Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. This positions kisspeptin one step upstream of the entire reproductive endocrine axis. Effects on LH/FSH are tightly regulated and physiological — unlike exogenous HCG it does not bypass HPG feedback. For premenopausal users, phase-aware tracking across 1-2 cycles informs the schedule; for perimenopausal users, HRT integration is the dominant question; for postmenopausal users, bone density and cardiovascular tone become the priority considerations.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Kisspeptin's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and Kisspeptin's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, Kisspeptin is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Female Physiology Applications

Bone Density

For bone density in female users, Kisspeptin is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Skin Health

Skin Health is one of the dimensions on which women track Kisspeptin response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Fertility

In the perimenopausal window, Kisspeptin for fertility produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Mood (Cycle-Related)

For mood (cycle-related) in female users, Kisspeptin is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-200 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-200 mcg	4–6 weeks initial cycle
Women's Health focus	SubQ	100-200 mcg	1-2x weekly SubQ
Maintenance phase	SubQ	70-200 mcg	Ongoing with periodic pauses

Dose timing for Kisspeptin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Kisspeptin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

Kisspeptin + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Kisspeptin's mechanism in female physiology protocols.
Kisspeptin + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Kisspeptin's mechanism in female physiology protocols.
Kisspeptin + Epithalon: Identified by Khavinson in St. Pairs naturally with Kisspeptin's mechanism in female physiology protocols.
Kisspeptin + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with Kisspeptin's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Investigational Research: Phase II in HSDD, fertility

Generally well tolerated. Used in fertility research safely. Affects gonadotropins — caution in hormone-sensitive conditions.

Lens-specific safety considerations for female physiology use of Kisspeptin: Generally well tolerated. Used in fertility research safely. Affects gonadotropins — caution in hormone-sensitive conditions. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Kisspeptin in reproductive physiology

PMID 23720496

Supporting

Kisspeptin and sexual brain processing in humans

PMID 28192302

Kisspeptin vs Related Peptides

Compound	Profile	Onset	Best For
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Can I use Kisspeptin during pregnancy or while trying to conceive?

Most peptide therapeutics, including Kisspeptin, do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

Is Kisspeptin appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

How will Kisspeptin interact with my cycle?

For pre-menopausal users, response to Kisspeptin often varies across follicular and luteal phases. The first 1–2 cycles should be used to track response by phase before settling on a fixed schedule. The compound's pharmacology is directly modulated by cyclical hormones, making phase-aware dosing particularly important.

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

What is the regulatory status of Kisspeptin?

Kisspeptin regulatory status: Investigational in the United States; WADA status not on prohibited list; research level phase ii in hsdd, fertility. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For female hormonal and cyclical use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What is the mechanism of action of Kisspeptin?

Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. This positions kisspeptin one step upstream of the entire reproductive endocrine axis. Effects on LH/FSH are tightly regulated and physiological — unlike exogenous HCG it does not bypass HPG feedback. For female hormonal and cyclical applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. The female physiology interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Clinical Protocol

Start a Kisspeptin Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified Kisspeptin and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 1302 Da
Sequence length: 10 aa
Half-life: ~28 min IV
WADA: Not on prohibited list
FDA: Investigational
Research: Phase II in HSDD, fertility

Stack Partners

Oxytocin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Kisspeptin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for Kisspeptin

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised